{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:02:43Z","timestamp":1778857363536,"version":"3.51.4"},"reference-count":21,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,23]]},"DOI":"10.1182\/bloodadvances.2022009448","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T18:36:50Z","timestamp":1670265410000},"page":"2129-2131","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Caplacizumab as frontline therapy in addition to standard treatment in iTTP"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-4508","authenticated-orcid":false,"given":"Joan","family":"Cid","sequence":"first","affiliation":[{"name":"1Apheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, Clinical Institute of Hematological and Oncological Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-833X","authenticated-orcid":false,"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[{"name":"1Apheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, Clinical Institute of Hematological and Oncological Diseases, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Catalonia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"10","key":"2023062316431745700_bib1","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2023062316431745700_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023062316431745700_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2023062316431745700_bib4","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2023062316431745700_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A\u00a0regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2023062316431745700_bib6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023062316431745700_bib7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023062316431745700_bib8","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"10","key":"2023062316431745700_bib9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"2023062316431745700_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023062316431745700_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/trf.15721","article-title":"Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura","volume":"60","author":"Colling","year":"2020","journal-title":"Transfusion"},{"issue":"4","key":"2023062316431745700_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/jca.21894","article-title":"Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: a nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura","volume":"36","author":"Pascual-Izquierdo","year":"2021","journal-title":"J\u00a0Clin Apher"},{"issue":"1","key":"2023062316431745700_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00277-021-04685-8","article-title":"Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era","volume":"101","author":"Del Rio-Garma","year":"2022","journal-title":"Ann Hematol"},{"issue":"6","key":"2023062316431745700_bib14","doi-asserted-by":"crossref","first-page":"e12802","DOI":"10.1002\/rth2.12802","article-title":"Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States","volume":"6","author":"Adeyemi","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"2023062316431745700_bib15","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc NY Pathol Soc"},{"issue":"1","key":"2023062316431745700_bib16","doi-asserted-by":"crossref","first-page":"103011","DOI":"10.1016\/j.transci.2020.103011","article-title":"Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI)","volume":"60","author":"Cid","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"10","key":"2023062316431745700_bib17","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2023062316431745700_bib18","doi-asserted-by":"crossref","first-page":"630.e1","DOI":"10.1016\/j.medcli.2021.03.040","article-title":"Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura","volume":"158","author":"Mingot Castellano","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"2023062316431745700_bib19","article-title":"Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura","author":"Pascual Izquierdo","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023062316431745700_bib20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/09537104.2021.1922883","article-title":"Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab","volume":"33","author":"Ditzel","year":"2022","journal-title":"Platelets"},{"issue":"8","key":"2023062316431745700_bib21","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/jth.15363","article-title":"Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab","volume":"19","author":"Schofield","year":"2021","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/2129\/2057609\/blooda_adv-2022-009448-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/2129\/2057609\/blooda_adv-2022-009448-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T16:32:42Z","timestamp":1687624362000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/10\/2129\/493418\/Caplacizumab-as-frontline-therapy-in-addition-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,5,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009448","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}